Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment

ASLNDelisted Stock  USD 0.60  0.03  4.76%   
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Shares of Aslan Pharmaceuticals were down 32 percent premarket on Thursday after the company released new data from a clinical study of eblasakimab, an atopic...

Read at marketwatch.com
marketwatch News
  

Aslan Pharmaceuticals Fundamental Analysis

We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Institutions

Shares Owned By Institutions Comparative Analysis

Aslan Pharmaceuticals is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Aslan Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Aslan Pharmaceuticals Related Equities

ANTXAN2 Therapeutics   21.90   
0%
100.0%
GLUEMonte Rosa   13.72   
0%
62.0%
LYRALyra Therapeutics   10.53   
0%
48.0%
IOBTIO Biotech   4.71   
0%
21.0%
CMPXCompass Therapeutics   4.49   
0%
20.0%
CTMXCytomX Therapeutics   3.92   
0%
17.0%
CGEMCullinan Oncology   2.75   
0%
12.0%
ADAGAdagene   1.30   
0%
5.0%
ASMBAssembly Biosciences   1.25   
0%
5.0%
AGIOAgios Pharm   1.24   
0%
5.0%
ACHLAchilles Therapeutics   0.93   
0%
4.0%
ACRVAcrivon Therapeutics,   0.80   
0%
3.0%
ANEBAnebulo Pharmaceuticals   0.70   
0%
3.0%
AVTEAerovate Therapeutics   0.38   
1.0%
0%
IVAInventiva   1.12   
5.0%
0%
GPCRStructure Therapeutics   1.78   
8.0%
0%
ERASErasca   2.05   
9.0%
0%
MLYSMineralys Therapeutics,   2.59   
11.0%
0%
NAMSNewAmsterdam Pharma   4.57   
20.0%
0%
TILInstil Bio   9.39   
42.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Consideration for investing in Aslan Stock

If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Equity Valuation
Check real value of public entities based on technical and fundamental data